Short-term efficacy and safety of concurrent chemoradiotherapy with paclitaxel and lobaplatin for advanced esophageal cancer
10.3760/cma.j.issn.1673-422X.2015.01.003
- VernacularTitle:紫杉醇联合洛铂同期放疗治疗中晚期食管癌的临床近期疗效及安全性
- Author:
Tao WANG
;
Junsheng YANG
- Publication Type:Journal Article
- Keywords:
Esophageal neoplasms;
Drug therapy,combination;
Paclitaxel;
Lobaplatin
- From:
Journal of International Oncology
2015;42(1):10-13
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the short-term efficacy and safety of concurrent chemoradiotherapy (CCRT) with paclitaxel and lobaplatin for advanced esophageal cancer.Methods Sixty-eight patients with advanced esophageal cancer were randomly divided into two groups according to random number table method:CCRT with paclitaxel and lobaplatin (TL group) and CCRT with DDP and 5-Fu (PF group).The CCRT regimen included radiotherapy at a total dose of 60-70 Gy,and concurrent paclitaxel 60 mg/m2 on d1,a fraction per week for 6-8 weeks,lobaplatin 30 mg/m2 on d2,a fraction per 3 weeks (TL group),and concurrent DDP 75 mg/m2 on d1,5-Fu 500 mg/m2,d1-5,CF 200 mg/m2,d1-5 (PF group).Results All 68 patients were evaluable for response.The response rates were 73.53％ in TL group and 50.00％ in PF group,the median progression-free survival were 13.0 months in TL group and 6.5 months in PF group.There were significant differences (x2 =4.023,P =0.040; x2 =4.512,P =0.034).The incidence rates of Ⅲ-ⅣW degree nausea and vomiting,granulocytopenia and thrombocytopenia were 5.88％ and 35.29％,20.59％ and 32.35％,32.35％ and 8.82％,and the differences were statistically significant (x2 ＝ 8.500,P =0.003 ; x2 =3.200,P =0.041; x2 =6.710,P =0.016).The incidence rates of Ⅲ-Ⅳ degree esophagitis in the two groups were 11.76％ and 17.65％,and there was no significant difference (x2 =1.45,P =0.493).Conclusion The efficacy of TL group in the treatment of advanced esophageal cancer is excellent,and all toxicities are well tolerated.So this protocol may be considered a main regimen in the treatment of advanced esophageal cancer.
